AzTrials
AzTrials

Recurrent Laryngeal Nerve PalsyVOCALENCT03976011

Post Thyroidectomy Echographic Method for Study of Vocal Fold Motion

A study testing Transcutaneous Laryngeal Ultrasonography in people with Recurrent Laryngeal Nerve Palsy and Postoperative Dysphonia, run by Assistance Publique - Hôpitaux de Paris at 5 sites in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

One of the major risks of endocrine surgery is recurrent nerve palsy (RNP), leading to vocal folds (VF) immobility. It happens in 5% of cases, leading to high morbidity: dysphonia, aspirations, impossibility to work. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Transcutaneous Laryngeal Ultrasonography
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
500 participants
Where
5 sitesFrance
Study dates
20 Oct 2019to Apr 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 18 years old patient and older
  • Free informed consent of the patient obtained during the preoperative consultation or, failing this, the day before the intervention during the preoperative hospitalization
  • Thyroid / parathyroid surgery scheduled within 3 months, regardless of the indication or extension
  • Affiliation to a social security system (recipient or assign) excluding AME.

Who cannot join

  • Known preoperative history of recurrent nerve palsy
  • History of thyroid or parathyroid surgery or cervicotomy for another pathology
  • History of laryngeal tumor or vocal folds
  • Patient under guardianship or curatorship or deprived of liberty or under judicial protection
  • Pregnant, breastfeeding and parturient women

Trial locations and contacts

5 sites in 1 country.

Christophe TRESALLET, MD PhD contact

01 42 17 66 39

christophe.tresallet@aphp.fr

5 sites in 1 country

France5 sites, 3 recruiting
  • CHU Nantes - Clinique de chirurgie Digestive et Endocrinienne

    Nantes, 44093

    Eric MIRALLIE, eric.mirallie@chu-nantes.fr

    Recruiting
  • Hopital Pitié-Salpêtrière

    Paris, 75013

    Terminated
  • Hopital Avicenne

    Paris

    Christophe TRESALLET, MD, 01 48 95 58 65, christophe.tresallet@aphp.fr

    Recruiting
  • Hopital Cochin

    Paris

    Terminated
  • Institut Gustave Roussy (IGR)

    Villejuif

    Dana HARTL, MD, PhD, dana.hartl@gustaveroussy.fr

    Recruiting

Other trials in France

About this study

Official title: Validation and Optimization Methods for a Quantitative Characterization of Motion Abnormalities of the Larynx With Echography

One of the major risks of endocrine surgery is recurrent nerve palsy (RNP), leading to vocal folds (VF) immobility. It happens in 5% of cases, leading to high morbidity: dysphonia, aspirations, impossibility to work. Guidelines recommend to systematically perform a nasofibroscopy before and after surgery to check vocal fold mobility. However, due to the decreasing number of specialists, the cost of decontamination, and discomfort of this procedure, these guidelines are insufficiently followed.

Transcutaneous Laryngeal Ultrasonography (TLU) appears a good alternative to nasofibroscopy in evaluating VF mobility, as assessed by the recent flourishing literature. Our team is a leader in this research by having developed a dedicated software, which provides objective measures of VF mobility. The aim of the present protocol is to validate the power of TLU for the diagnosis of RNP on a large cohort of patients operated on endocrine surgery. It is a prospective multicentric study that will blindly compare TLU and nasofibroscopy, the latter being the gold standard. TLU is cost effective and painless; its learning curve is fast. If validated, it may be offered as a good alternative to nasofibroscopy in RNP detection and prognosis.

Read the detailed description

The rationale of this study is that Transcutaneous Laryngeal Ultrasonography (TLU) may be a relevant and reliable tool in assessing vocal folds (VF) paralysis secondary to endocrine surgery (thyroid and parathyroid surgery). According to the literature and to our own publications, subjective impression of VF (im)mobility seems sufficient to diagnose a paralysis. However, the investigators think that objective measures, based on a dedicated semi-automatic software, may offer a much powerful implement and needs to be compared to the gold standard technique, i.e. the nasofibroscopy (NF), in a large prospective multicentric cohort.

In a preliminary study, the investigators described TLU anatomical landmarks first in an ex vivo study and secondary in a prospective study based on 50 patients with VF paralysis compared to 50 controls. These three landmarks, the two arytenoids and the anterior insertion of the two vocal folds on the thyroid cartilage, are easy to recognize, and independent of the postoperative delay and the person performing TLU. They define two symmetrical hemi-larynges in healthy subjects. The investigators designed an original software, aiming at offering two quantitative criteria of laryngeal mobility and symmetry, taking into account motion symmetry (symmetry index) and amplitude (mobility index) of the two hemi-larynges. When a subject presented with a unilateral VF paralysis, the mean symmetry index was significantly larger compared to the control group (20.4% ±13.8% versus 6.7% ±4.7%, p<0.0001) and the mean lower mobility index was significantly smaller (2.2% ±17.4% versus 20.5% ±14.8%, p<0.0001). The sensitivity and specificity of this first version of our automatized protocol were 82%.

The aim of the present study is to validate TLU as an alternative to NF in a large independent cohort of patients operated on endocrine surgery. The main goal is to improve the sensitivity and specificity of the objective measures and implement new parameters in the software. By a ready to use tool, the investigators would like to offer the opportunity to any practitioner to assess and quantify VF (im)mobility with their usual US machine.

The subjects will be recruited in the three different clinical centers, highly specialized in endocrine surgery. The aim of 500 subjects included seems feasible thanks to the high activity of these centers. Moreover the latter already have sufficient and qualified staff and technical tools to perform clinical follow up, US, and NF.

The technical acquisition is as follow. The TLU is performed with a 7-14 MHz linear probe, using a portable machine. Subjects are lying on the back, neck slightly extended, with the probe placed over the laryngeal prominence of the thyroid cartilage, including the arytenoids in the axial view. The images are acquired in B-mode, during normal breathing at rest. Typical values for acquisition are: frequency 10 MHz, depth of field of view 4 cm, mechanical index 0.6, gain 45%, dynamic range 85 decibels. A video clip of 10 seconds (30 images per second) is recorded in order to include 5 to 6 complete respiratory cycles. Two images corresponding to physiological abduction and adduction during the same breath cycle are selected. The landmarks, previously described, are selected on the images and tracked by the software.

All patients operated on endocrine surgery in the three referral centers and responding to the inclusion criteria will be included after obtaining their writing consent. The gold standard NF will be performed between D1 and D15, as usually performed after these surgeries. TLU will be performed during the same time period by an investigator blind to the NF results. The subject will be his own control, NF and TLU being compared. When facing VF immobility, the subject will benefit from the usual clinical follow up: consultation with NF at 6 weeks and 6 months. TLU will be added to these appointments.

Being tested
Transcutaneous Laryngeal Ultrasonography
Keywords
Postoperative dysphonia, Thyroidectomy, Parathyroidectomy, Inferior laryngeal nerve palsy, Trans laryngeal ultrasonography, Quantitative vocal fold motion evaluation, Postoperative recurrent Laryngeal Nerve Palsy
Medical subject headings
Vocal Cord Paralysis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Transcutaneous Laryngeal UltrasonographyDevice

    TLU will be performed during the same time period of The gold standard NF (who is performed as usually after endocrine surgeries) by an investigator blind to the NF results, between D1 and D15.

    The subject will be his own control, NF and TLU being compared. When facing VF immobility, the subject will benefit from the usual clinical follow up: consultation with NF at 6 weeks and 6 months. TLU will be added to these appointments.

Study groups in NCT03976011
Study groupRoleWhat they receive
Transcutaneous Laryngeal UltrasonographyExperimentalAll patients operated on endocrine surgery in the three referral centers and responding to the inclusion criteria will be included after obtaining their writing consent. The gold standard NF will be performed between D1 and D15, as usually performed after these surgeries. TLU will be performed during the same time period by an investigator blind to the NF results. The subject will be his own control, NF and TLU being compared. When facing VF immobility, the subject will benefit from the usual clinical follow up: consultation with NF at 6 weeks and 6 months. TLU will be added to these appointments.
Receives: Device: Transcutaneous Laryngeal Ultrasonography

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Diagnostic performance associated with the postoperative quantitative TLU (i.e. measured by asymmetry in vocal cord mobility obtained with our dedicated software of image analysis) for the diagnostic of postoperative recurrent nerve palsy (RNP).

    The diagnostic performance of the postoperative measurement of asymmetry in vocal cord mobility obtained with the quantitative TLU will be evaluated by the area under the roc curve and its 95% confidence interval. The gold standard for diagnosis of postoperative RNP will be the nasofibroscopy performed between Day 1 and Day15.

    Measured: Between Day 1(the day after the surgery) and Day 15

Secondary outcomes (14)
  1. Diagnostic performance associated with the postoperative qualitative TLU (i.e. obtained by the operator during TLU, without the use of our dedicated software for the diagnostic of postoperative recurrent nerve palsy (RNP).

    The diagnostic performance of the postoperative qualitative evaluation of asymmetry in vocal cord mobility obtained by the operator during TLU will be evaluated using sensitivity, specificity, positive and negative predictive value and and their 95% confidence interval. The gold standard for diagnosis of postoperative RNP will be the nasofibroscopy performed between Day 1 and Day 15.

    Measured: Between Day 1(the day after the surgery) and Day 15

  2. Predictive performance associated with the postoperative quantitative TLU for the diagnosis of final recovery of RNP, among subjects with postoperative RNP.

    The predictive performance of the measurement of asymmetry in vocal cord mobility obtained with the postoperative quantitative TLU will be evaluated among patients with postoperative RNP by the area under the roc curve and its 95% confidence interval. The gold standard for diagnosis of final recovery of RNP will be the nasofibroscopy performed 6 months after surgery.

    Measured: 6 months after surgery

  3. Predictive performance associated with the postoperative qualitative TLU for the diagnosis of final recovery of RNP, among subjects with postoperative RNP.

    The predictive performance of the postoperative qualitative evaluation of asymmetry in vocal cord mobility obtained by the operator during TLU will be evaluated using sensitivity, specificity, positive and negative predictive value and and their 95% confidence interval. The gold standard for diagnosis of final recovery of RNP will be the nasofibroscopy performed 6 months after surgery.

    Measured: 6 months (e.g. 6 months after surgery)

  4. Predictive performance associated with the quantitative TLU performed 6 weeks after surgery for the diagnosis of final recovery of RNP, among subjects with postoperative RNP.

    The predictive performance of the measurement of asymmetry in vocal cord mobility obtained with the quantitative TLU 6 weeks after surgery will be evaluated among patients with postoperative RNP by the area under the roc curve and its 95% confidence interval. The gold standard for diagnosis of final recovery of RNP will be the nasofibroscopy performed 6 months after surgery.

    Measured: 6 months after surgery

  5. Predictive performance associated with the qualitative TLU performed 6 weeks after surgery for the diagnosis of final recovery of RNP, among subjects with postoperative.

    The predictive performance of the qualitative evaluation of asymmetry in vocal cord mobility obtained by the operator during TLU performed 6 weeks after surgery will be evaluated using sensitivity, specificity, positive and negative predictive value and and their 95% confidence interval. The gold standard for diagnosis of final recovery of RNP will be the nasofibroscopy performed 6 months after surgery.

    Measured: 6 months after surgery

  6. Diagnostic performance associated with the quantitative TLU performed 6 months after surgery for the diagnosis of final recovery of RNP, among subjects with postoperative RNP.

    The diagnostic performance of the measurement of asymmetry in vocal cord mobility obtained with the quantitative TLU 6 months after surgery will be evaluated among patients with postoperative RNP by the area under the roc curve and its 95% confidence interval. The gold standard for diagnosis of final recovery of RNP will be the nasofibroscopy performed 6 months after surgery.

    Measured: 6 months after surgery

  7. Diagnostic performance associated with the qualitative TLU performed 6 months after surgery for the diagnosis of final recovery of RNP, among subjects with postoperative RNP.

    The diagnostic performance of the qualitative evaluation of asymmetry in vocal cord mobility obtained by the operator during TLU performed 6 months after surgery will be evaluated using sensitivity, specificity, positive and negative predictive value and and their 95% confidence interval. The gold standard for diagnosis of final recovery of RNP will be the nasofibroscopy performed 6 months after surgery.

    Measured: 6 months after surgery

  8. Correlation between the postoperative Voice Handicap Index (VHI) and the postoperative quantitative TLU.

    Pearson correlation coefficient between postoperative quantitative TLU and VHI

    Measured: Between Day 1(the day after the surgery) and Day 15

  9. Correlation between the Voice Handicap Index (VHI) measured 6 weeks after surgery and the quantitative TLU measured 6 weeks after surgery, among subjects with postoperative RNP.

    Pearson correlation coefficient between quantitative TLU and VHI at 6 weeks

    Measured: 6 weeks after surgery (+/- 15 days)

  10. Correlation between the Voice Handicap Index (VHI) measured 6 months after surgery and the quantitative TLU measured 6 months after surgery, among subjects with postoperative RNP.

    Pearson correlation coefficient between quantitative TLU and VHI at 6 months

    Measured: 6 months after surgery

  11. Pearson correlation coefficient between postoperative quantitative TLU and loss or diminution of the intraoperative stimulation of the inferiors laryngeal nerves, expressed in microvolts, measured during the surgery.

    Measured: Between Day 1(the day after the surgery) and Day 15

  12. Postoperative patient's satisfaction regarding TLU examination: six-point satisfaction questionnaire

    Patient's satisfaction regarding TLU examination will be evaluated using a structured questionnaire (Strongly disagree; Slightly disagree; Neither agree nor disagree; Slightly agree; Strongly agree; Without opinion)

    Measured: Between Day 1 and Day 15

  13. Postoperative patient's satisfaction regarding nasofibroscopic examination: six-point satisfaction questionnaire

    Postoperative patient's satisfaction regarding nasofibroscopic examination will be evaluated using a structured six-point satisfaction six-point satisfaction questionnaire (Strongly disagree; Slightly disagree; Neither agree nor disagree; Slightly agree; Strongly agree; Without opinion)

    Measured: Between Day 1 and Day 15

  14. Comparison between the costs associated with the nasofibroscopy of the one hand, and the TLU on the other hand.

    The costs of nasofibroscopy on the one hand, and the TLU on the other, will be determined taking into account of the french social security system and its repayment as well as the time required to carry out the examinations, the purchase cost of the devices and its maintenance. The costs associated with the two examinations will be compared using the incremental cost-effectiveness ratio (ICER) and its 95% confidence interval

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Jun 2019
  2. Study start20 Oct 2019
  3. Primary completionJan 2024 (estimated)
  4. Study completionApr 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03976011
Sponsor's protocol ID
K170921J
Other IDs
2018-A02951-54
Acronym
VOCALE
Status last verified
May 2023
First submitted
24 May 2019
Last updated
7 Jun 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Bergeret-Cassagne H, Lazard DS, Lefort M, Hachi S, Leenhardt L, Menegaux F, Russ G, Tresallet C, Frouin F. Sonographic Dynamic Description of the Laryngeal Tract: Definition of Quantitative Measures to Characterize Vocal Fold Motion and Estimation of Their Normal Values. J Ultrasound Med. 2017 May;36(5):1037-1044. doi: 10.7863/ultra.16.05014. Epub 2017 Jan 10.

    PubMed 28072470
  • Lazard DS, Bergeret-Cassagne H, Lefort M, Leenhardt L, Russ G, Frouin F, Tresallet C. Transcutaneous Laryngeal Ultrasonography for Laryngeal Immobility Diagnosis in Patients with Voice Disorders After Thyroid/Parathyroid Surgery. World J Surg. 2018 Jul;42(7):2102-2108. doi: 10.1007/s00268-017-4428-2.

    PubMed 29299645

Questions about this trial

What is this clinical trial studying?

A study testing Transcutaneous Laryngeal Ultrasonography in people with Recurrent Laryngeal Nerve Palsy and Postoperative Dysphonia, run by Assistance Publique - Hôpitaux de Paris at 5 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 7 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Christophe TRESALLET, MD PhD (01 42 17 66 39, christophe.tresallet@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Diagnostic performance associated with the postoperative quantitative TLU (i.e. measured by asymmetry in vocal cord mobility obtained with our dedicated software of image analysis) for the diagnostic of postoperative recurrent nerve palsy (RNP). (time frame: Between Day 1(the day after the surgery) and Day 15). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03976011, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jun 2023.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in